Novo sets 2030 goals as shares fall as much as 9%, Telix agrees a $2.35B merger with ITM, and Insmed's ARIKAYCE wins FDA Priority Review.
Read digest →Amneal generic lanreotide FDA approval + immediate launch, Novo denecimig CHMP for hemophilia A, Lilly Inluriyo+Verzenio FDA approval for ESR1-mutated BC.
Read digest →Zealand's glepaglutide wins EU CHMP backing for short bowel syndrome, Keytruda+Padcev gets a perioperative MIBC nod, and Sandoz signs an emicizumab deal.
Read digest →Novo signs an Orbis oral macrocycle deal worth up to $1.4B, Roche's Lunsumio hits in Phase 3 CELESTIMO, and Halozyme upsizes convertible notes to $1.3B.
Read digest →FDA approves Ultragenyx FAYUVI as first-ever Sanfilippo Type A treatment, Novo Nordisk rebrands to 'Novo', Dualitas-Roche $1B bispecific I&I deal.
Read digest →Novo Nordisk-Anthropic Claude Science deal, Zealand Metabolic Frontier 2030, Circle Pharma $92.5M macrocycle Series E, Vera TRUTAKNA ORIGIN 3 results.
Read digest →Samsung-PolyPeptide CHF 1.46B tender main offer opens, Scholar Rock Isembyld SMA launch after FDA approval, Cogent bezuclastinib AdvSM NDA accepted.
Read digest →Corbus CRB-913 5% at 60 mg in Phase 1b obesity, Insmed raises BRINSUPRI FY guidance to $1.25-1.4B, Kelun trastuzumab botidotin 11.1 vs 4.4-mo PFS in JCO.
Read digest →Morgan Stanley cuts Novo Nordisk to Underweight on semaglutide patent cliff, HSBC lifts target to DKK 320, Corbus CANYON-1 Monday morning topline countdown.
Read digest →Pharming Joenja wins pediatric APDS approval, Penn Nature Health flags GLP-1 side effects from 400K Reddit posts, Pediatrics finds 310x pediatric GLP-1 rise.
Read digest →AbbVie atogepant clears LUNA Phase 3 menstrual migraine, Telix Pixclara PDUFA hits Sept 11, Corbus CANYON-1 topline data call set for Sept 14.
Read digest →Roche Enspryng wins FDA Priority Review for MOGAD, MannKind licenses inhaled GLP-1 to Rose, Amgen MariTide targets 4-6 doses/year, Solstice raises $225M.
Read digest →Ascendis reports Week 52 reACHin infant navepegritide growth data at ESPE, Roivant PHocus draws $55 Piper target, Moonwalk raises $70M for adipose RNAi.
Read digest →Pulmovant mosliciguat PVR -56.3% at wk 16 in PH-ILD, Structure aleniglipron 16.2% at 72 wks + ACCG-2671 amylin data, Ascendis reACHin sentinel at ESPE.
Read digest →Novo semaglutide clears STEP Young Phase 3 in children 6-11, ziltivekimab HF trials HERMES + ATHENA halted, Ascendis reACHin sentinel data at ESPE Tuesday.
Read digest →Novartis + BMS pause autoimmune CAR-T trials after 3 deaths, Transgene TG4050 shows 100% 3-yr DFS in head/neck, PRV program extended through 2029.
Read digest →Novartis pelacarsen Phase 3 misses CV endpoint, AstraZeneca Etcamah wins US approval for ESR1 breast cancer, Alteogen-Novartis $3.2B Hybrozyme deal.
Read digest →FDA approves Ionis Zanvastro for Alexander disease, AbbVie etentamig hits dual endpoints in MM, Akeso ivonescimab beats Keytruda, Medicus-Pfizer ink ADC deal.
Read digest →